Skip to content

The application of evodia patch combined with 5-HT3 receptor antagonist in patients with acute myeloid leukemia chemotherapy to discontinue emetic

The application of evodia patch combined with 5-HT3 receptor antagonist in patients with acute myeloid leukemia chemotherapy to discontinue emetic

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000502
Enrollment
Unknown
Registered
2025-03-11
Start date
2023-04-30
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy related nausea and vomiting

Interventions

Control group:Paste flour on Zusanli acupoint and tropisetron hydrochloride injection
Experimental group:Wu Zhuyu sticks to the acupuncture points of Zusanli and Tropisetron hydrochloride injection

Sponsors

Beijing University People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
15 Years to 72 Years

Inclusion criteria

Inclusion criteria: Diagnosis of acute myeloid leukemia (non-M3) according to WHO criteria 2016; Patients with prior chemotherapy and vomiting; The chemotherapy regimens were HAA IA medium-dose cytarabine and CLAG; Agree to participate in clinical studies and sign informed consent; No serious diseases such as brain liver kidney (serum creatinine= 1.5× upper limit of normal (ULN); or serum creatinine >1.5× ULN 24-hour creatinine clearance =50mL/min (using the Cockcroft-Gault formula); serum albumin= 3.0 g/dL; Serum total bilirubin = 1.5×ULN; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =2.5×ULN; Amylase = 1.5× ULN Lipase = 1.5×ULN; PT APTT AND INR = 1.5× ULN. Cardiac function indicators: ejection fraction (EF) > 50% pulmonary systolic blood pressure =50mmHg)

Exclusion criteria

Exclusion criteria: Those who are allergic to the study drug ingredient or its analogues; Those with poor skin condition; Those who have received autologous or allogeneic hematopoietic stem cell transplantation; The patient has nausea and vomiting due to neuropathic vomiting gastrointestinal obstruction and increased intracranial pressure

Design outcomes

Primary

MeasureTime frame
Incidence of nausea and vomiting;

Secondary

MeasureTime frame
The severity of nausea and vomiting;Time of nausea and vomiting;

Countries

China

Contacts

Public ContactLIUZHE

Beijing University People's Hospital

763687195@qq.com18101200641

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026